Document Detail

Addition of fexofenadine to inhaled corticosteroid therapy to reduce inflammatory biomarkers in atopic asthma.
MedLine Citation:
PMID:  16200817     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: We previously showed that H1-antihistamines may shift the PC20 (provocation concentration that caused a decrease in forced expiratory volume in 1 second of 20%) threshold to adenosine monophosphate (AMP) challenge but may paradoxically prolong recovery. OBJECTIVES: To measure AMP recovery using a constant predetermined AMP PC20 and to evaluate whether fexofenadine use confers add-on effects to treatment with either fluticasone propionate alone or combined fluticasone propionate-salmeterol. METHODS: Fourteen atopic patients with mild-to-moderate asthma (forced expiratory volume in 1 second of 76%) completed a double-blind, randomized, crossover study consisting of 3-week treatment blocks of either fluticasone propionate-salmeterol, 250 microg twice daily, or fluticasone propionate alone, 250 microg twice daily, in conjunction with either fexofenadine, 180 mg once daily, or matched placebo. Recovery after a predetermined AMP PC20 challenge was measured (primary outcome), along with exhaled nitric oxide levels, plasma eosinophil cationic protein levels, peripheral eosinophil counts, pulmonary function, diary card outcomes, and quality of life (all secondary outcomes). RESULTS: There were no differences in any of the primary or secondary outcomes when fexofenadine was added to treatment with either fluticasone propionate-salmeterol or fluticasone propionate alone. The mean AMP recovery time was 25.0 vs 23.4 minutes for fexofenadine and placebo, respectively, as add-on to fluticasone-salmeterol and 22.5 vs 23.9 minutes, respectively, as add-on to fluticasone alone. CONCLUSION: Fexofenadine did not affect recovery to a fixed dose of AMP challenge or any other surrogate inflammatory markers when given as add-on therapy to corticosteroid-treatedatopic asthmatic patients.
Tom C Fardon; Daniel K C Lee; Melissa R Hodge; Brian J Lipworth
Related Documents :
11061767 - Effectiveness of a clinical pathway for inpatient asthma management.
8720227 - Treatment of mild asthma with inhaled corticosteroids: is discontinuation of therapy po...
19076547 - Validation of a questionnaire for assessment of asthma patient knowledge and behaviour.
7728627 - Chronic asthma and chiropractic spinal manipulation: a randomized clinical trial.
22588987 - Correlates of motivation to change in pathological gamblers completing cognitive-behavi...
23949617 - Longitudinal associations between depressive symptoms and body mass index in a 20-year ...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology     Volume:  95     ISSN:  1081-1206     ISO Abbreviation:  Ann. Allergy Asthma Immunol.     Publication Date:  2005 Sep 
Date Detail:
Created Date:  2005-10-04     Completed Date:  2005-10-27     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9503580     Medline TA:  Ann Allergy Asthma Immunol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  259-65     Citation Subset:  IM    
Asthma and Allergy Research Group, University of Dundee, Ninewells Hospital and Medical School, Dundee, Scotland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adenosine Monophosphate / immunology
Administration, Inhalation
Adrenal Cortex Hormones / administration & dosage*
Albuterol / analogs & derivatives,  therapeutic use
Androstadienes / therapeutic use
Anti-Allergic Agents / therapeutic use*
Asthma / drug therapy*
Biological Markers
Bronchial Provocation Tests
Drug Therapy, Combination
Eosinophil Cationic Protein / blood,  drug effects
Eosinophils / drug effects
Hypersensitivity, Immediate / drug therapy*
Inflammation / immunology
Nitric Oxide / analysis
Respiratory Function Tests
Terfenadine / analogs & derivatives*,  therapeutic use
Treatment Outcome
Reg. No./Substance:
0/Adrenal Cortex Hormones; 0/Androstadienes; 0/Anti-Allergic Agents; 0/Biological Markers; 10102-43-9/Nitric Oxide; 138452-21-8/fexofenadine; 18559-94-9/Albuterol; 50679-08-8/Terfenadine; 61-19-8/Adenosine Monophosphate; 89365-50-4/salmeterol; 90566-53-3/fluticasone; EC 3.1.27.-/Eosinophil Cationic Protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years.
Next Document:  Analysis of vascular endothelial growth factor levels in induced sputum samples from patients with c...